GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xilio Therapeutics Inc (NAS:XLO) » Definitions » Gross Profit

XLO (Xilio Therapeutics) Gross Profit : $4.62 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Xilio Therapeutics Gross Profit?

Xilio Therapeutics's gross profit for the three months ended in Sep. 2024 was $2.26 Mil. Xilio Therapeutics's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $4.62 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Xilio Therapeutics's gross profit for the three months ended in Sep. 2024 was $2.26 Mil. Xilio Therapeutics's Revenue for the three months ended in Sep. 2024 was $2.26 Mil. Therefore, Xilio Therapeutics's Gross Margin % for the quarter that ended in Sep. 2024 was N/A%.

Xilio Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Xilio Therapeutics Gross Profit Historical Data

The historical data trend for Xilio Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xilio Therapeutics Gross Profit Chart

Xilio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
- - - - -

Xilio Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 2.36 2.26

Competitive Comparison of Xilio Therapeutics's Gross Profit

For the Biotechnology subindustry, Xilio Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xilio Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Xilio Therapeutics's Gross Profit falls into.



Xilio Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Xilio Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Xilio Therapeutics's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=2.263 - 0
=2.26

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.62 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Xilio Therapeutics's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=2.26 / 2.263
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Xilio Therapeutics  (NAS:XLO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Xilio Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Xilio Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Xilio Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Xilio Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
828 Winter Street, Suite 300, Waltham, MA, USA, 02451
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Executives
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Katarina Luptakova officer: Chief Medical Officer C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Christopher James Frankenfield officer: Chief Operating Officer C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Kevin M. Brennan officer: SVP, FINANCE AND ACCOUNTING C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Edward C English officer: Principal Accounting Officer 828 WINTER STREET, WALTHAM MA 02451
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Robert W. Ross director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Yuan Xu director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Bain Capital Life Sciences Fund Ii, L.p. 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Atlas Venture Opportunity Fund I, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Sv7 Impact Medicine Fund Lp 10 percent owner 71 KINGSWAY, LONDON X0 WC2B 6ST
Bcls Ii Investo (gp), Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investco, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Investors Ii, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Rivervest Venture Fund Iv, L.p. 10 percent owner 101 SOUTH HANLEY ROAD, SUITE 1850, ST. LOUIS MO 63105